These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33063259)

  • 1. Genetic Testing for Breast Cancer Patients: Is Everyone Who Needs a Test Getting a Test?
    Heller DR; Friedrich AU; Killelea BK
    Ann Surg Oncol; 2021 Jan; 28(1):18-19. PubMed ID: 33063259
    [No Abstract]   [Full Text] [Related]  

  • 2. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
    Barnes-Kedar IM; Plon SE
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2: to test or not to test.
    Brandt RT; Lynch HT
    Breast Cancer Res Treat; 2001 May; 67(2):187-8. PubMed ID: 11519868
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast cancer risk assessment and genetic testing: complexities, conundrums, and community.
    Peshkin BN
    Breast Dis; 2006-2007; 27():1-3. PubMed ID: 17917137
    [No Abstract]   [Full Text] [Related]  

  • 5. US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.
    Newman L
    JAMA Surg; 2019 Oct; 154(10):895-896. PubMed ID: 31429868
    [No Abstract]   [Full Text] [Related]  

  • 6. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 7. Hereditary breast cancer and genetic counseling in young women.
    Brunet J
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():7-9. PubMed ID: 20711663
    [No Abstract]   [Full Text] [Related]  

  • 8. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 9. BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    Printz C
    Cancer; 2016 Apr; 122(8):1149. PubMed ID: 27061519
    [No Abstract]   [Full Text] [Related]  

  • 10. Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    Printz C
    Cancer; 2020 Feb; 126(4):693. PubMed ID: 31995244
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
    Silva E; Lynch H
    Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Who must be referred for genetic counseling?].
    Monnerat C; Dobbie M
    Ther Umsch; 2021 Apr; 78(3):145-148. PubMed ID: 33775137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incentive.
    Matloff ET
    J Genet Couns; 2012 Apr; 21(2):211-2. PubMed ID: 22160559
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Bonadona V; Sinilnikova OM; Lenoir GM; Lasset C
    J Natl Cancer Inst; 2002 Oct; 94(20):1582-3; author reply 1583-4. PubMed ID: 12381714
    [No Abstract]   [Full Text] [Related]  

  • 17. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One risk fits all?
    De Bock GH; Mourits MJ; Oosterwijk JC
    J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
    [No Abstract]   [Full Text] [Related]  

  • 19. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Communicating BRCA1 and BRCA2 genetic test results.
    Gadzicki D; Wingen LU; Teige B; Horn D; Bosse K; Kreuz F; Goecke T; Schäfer D; Voigtländer T; Fischer B; Froster U; Welling B; Debatin I; Weber BH; Schönbuchner I; Nippert I; Schlegelberger B;
    J Clin Oncol; 2006 Jun; 24(18):2969-70; author reply 2970-1. PubMed ID: 16782939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.